Pfizer’s Foes in Bench Trial Over Vyndamax Copies Down to Hikma

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench ...

Pfizer’s Deal With Hikma Ends Patent Trial on Vyndamax Copy (1)

Pfizer Inc. agreed to end a dispute with Hikma Pharmaceuticals Plc after one day of trial, resolving the last remaining ...
Hosted on MSN

Pfizer’s long-awaited Lyme vaccine fails to impress in study

(Bloomberg) -- Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result as fewer-than-expected infections in the pivotal study made ...
Bloomberg L.P.

Pfizer Wins €1.9 Billion Covid Vaccine Case With Poland, Romania

Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines the two countries refused to take delivery of during the pandemic, handing ...
Reuters

Pfizer weighing sale of women's health portfolio: Bloomberg

(Reuters) - U.S. drugmaker Pfizer Inc is considering options, including a sale of its women's health portfolio, Bloomberg reported on Thursday, citing sources familiar with the matter. A sale of the ...
RAPS

Recon: FDA approves Merck’s Keytruda for advanced endometrial cancer; Pfizer recalls some BP drug lots due to nitrosamine impurity

Recon: FDA approves Merck’s Keytruda for advanced endometrial cancer; Pfizer recalls some BP drug lots due to nitrosamine impurity Welcome to Regulatory Reconnaissance, your daily regulatory news and ...
RAPS

Recon: US signs $3.2B deal for Pfizer-BioNTech vaccines; Novartis said to lean toward spinoff of generics unit

Recon: US signs $3.2B deal for Pfizer-BioNTech vaccines; Novartis said to lean toward spinoff of generics unit Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence ...